Howard Bernstein

SQZ Biotech (United States) — United States

Medicine · Health Sciences

24h-index2.3kcitations115works5.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Anesthesia and Pain Management(26), CAR-T cell therapy research(24), Immunotherapy and Immune Responses(21), Nausea and vomiting management(12), Virus-based gene therapy research(11)

Publications115 total

Final outcomes analysis of the cell product SQZ‐PBMC‐HPV Phase 1 trial in incurable HPV16+ solid tumors shows improved overall survival in patients with increased CD8+ T cell tumor infiltration
Molecular Carcinogenesis·2024· 5 citedOpen Access
594 SQZ-PBMC-HPV-101: Increased overall survival in a subset of patients with recurrent, locally advanced, or metastatic HPV16<sup>+</sup>tumors treated with cell-based vaccine, SQZ-PBMC-HPV
Regular and Young Investigator Award Abstracts·2023Open Access
692 COMMANDER-001: safety data from a phase I/II dose escalation/expansion study of SQZ-eAPC-HPV, a cell-based mRNA therapeutic cancer vaccine for HPV16+ solid tumors
Regular and Young Investigator Award Abstracts·2023Open Access
693 SQZ-AAC-HPV-101: initial data from a phase I dose escalation/expansion study of SQZ-AAC-HPV, a red blood cell-based therapeutic cancer vaccine for HPV16+ solid tumors
Regular and Young Investigator Award Abstracts·2023Open Access
Phase 1 study to determine the safety and dosing of autologous PBMCs modified to present HPV16 antigens (SQZ-PBMC-HPV) in HLA-A*02+ patients with HPV16+ solid tumors
Investigational New Drugs·2023· 6 citedOpen Access
Phase 1 study to determine the safety and dosing of autologous PBMCs modified to present HPV16 antigens (SQZ- PBMC-HPV) in HLA-A*02+ patients with HPV16+ Solid Tumors
Research Square (Research Square)·2022Open Access
224 Generation of cell therapies for diverse applications using microfluidic Cell Squeeze<sup>®</sup>manufacturing technology
Regular and Young Investigator Award Abstracts·2022Open Access
638 COMMANDER-001: a phase 1/2, first-in-human, multicenter, open label study of SQZ-eAPC-HPV as monotherapy and with pembrolizumab in patients with HPV16+ recurrent, locally advanced, or metastatic solid tumors (trial in progress)
Regular and Young Investigator Award Abstracts·2022Open Access
Engineered red blood cells (activating antigen carriers) drive potent T cell responses and tumor regression in mice
Frontiers in Immunology·2022· 9 citedOpen Access
Cell Squeeze: driving more effective CD8 T-cell activation through cytosolic antigen delivery
Immuno-Oncology Technology·2022· 12 citedOpen Access
Abstract 2853: Co-delivery of antigen-encoding mRNA and signal 2/3 mRNAs to PBMCs by Cell Squeeze® technology generates SQZ™ eAPCs that prime CD8+T cells in a humanized mouse model
Cancer Research·2022
Engineered RBCs Encapsulating Antigen Induce Multi-Modal Antigen-Specific Tolerance and Protect Against Type 1 Diabetes
Frontiers in Immunology·2022· 14 citedOpen Access
Microfluidic Squeezing Enables MHC Class I Antigen Presentation by Diverse Immune Cells to Elicit CD8+ T Cell Responses with Antitumor Activity
The Journal of Immunology·2022· 21 citedOpen Access
48MO SQZ-PBMC-HPV-101: Preliminary results of a first-in-human, dose-escalation study of a cell-based vaccine in HLA A*02+ patients with recurrent, locally advanced, or metastatic HPV16+ solid tumors
Annals of Oncology·2021· 3 cited
156 RBC-derived, activating antigen carriers (SQZ AACs) prime potent T cell responses and drive tumor regression in vivo
Regular and Young Investigator Award Abstracts·2021· 1 citedOpen Access
211 SQZ™ eAPCs generated from PBMCs by delivery of multiple mRNAs encoding for antigens, costimulatory proteins, and engineered cytokines
Regular and Young Investigator Award Abstracts·2021Open Access
Abstract 1525: Enhancing potency of antigen presenting cells via signal 2/3 mRNA engineering through Cell Squeeze® technology
Cancer Research·2021· 1 cited
Abstract 1523: Cell Squeeze® delivery of antigen-encoding mRNA enables human PBMCs to drive antigen-specific CD8+ T cell responses for diverse clinical applications
Cancer Research·2021
Abstract 1524: Peripheral blood mononuclear cells engineered via microfluidic Cell Squeeze® technology to generate APCs that drive mutant-KRas-specific CD8+ T cell responses
Cancer Research·2021· 1 cited
Initial results of a first-in-human, dose escalation study of a cell-based vaccine in HLA A*02+ patients (pts) with recurrent, locally advanced or metastatic HPV16+ solid tumors: SQZ-PBMC-HPV-101.
Journal of Clinical Oncology·2021· 6 cited
page 1 of 6Next →

Frequent Co-authors

Yaakov Beilin(17), Róbert Langer(10), Scott Loughhead(7), Victor C. Yang(7), Carol Bodian(7), Armon Sharei(6), Barbara Zucker-Pinchoff(6), Jeffrey Zahn(6), Sabera Hossain(5), Donald E. Chickering(4), Julie A. Straub(4), Meg A. Rosenblatt(3), Wendy J. Zenzen(3), Sharon E. Abramovitz(3), Ricardo Zwirtes(3), Julia Jennings(3), Joaquina Baranda(3), Wade T. Iams(3), Monica Mita(3), Michael S. Gordon(3)